Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors

• Derrek P. Hibar,

  Roles Writing – review & editing

  Affiliation Personalized Healthcare Analytics, Genentech, Inc., South San Francisco, California, United States of America

  ⨯
• George D. Demetri,

  Roles Writing – review & editing

  Affiliation Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Solange Peters,

  Roles Writing – review & editing

  Affiliation Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

  ⨯
• Jessica Davies,

  Roles Writing – review & editing

  Affiliation Personalized Healthcare Data Science, Roche Products Ltd, Welwyn Garden City, United Kingdom

  ⨯
• Olivier Humblet,

  Roles Writing – review & editing

  Affiliation Quantitative Sciences, Flatiron Health Inc., New York, New York, United States of America

  ⨯
• Sophia L. Maund,

  Roles Writing – review & editing

  Affiliation Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, United States of America

  ⨯
• Laura Perez

  Roles Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing

  * E-mail: laura.perez.lp1@roche.com

  Affiliation Personalized Healthcare Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  https://orcid.org/0000-0002-1695-7494

  ⨯